

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Christian Wissgott

Page 1/2

Tuesday, January 28, 2020

ROOM 1 - MAIN ARENA 1

09:30 – 11:00 Latest insights on safety and efficacy of drug-coated devices

MODERATOR:

Dierk Scheinert

William Gray

PANEL:

Hiroyoshi Yokoi

Andrew Holden

Marianne Brodmann

Peter Schneider

Thomas Zeller

Eva Freisinger

FOCUS ON PACLITAXEL SAFETY

- | | |
|---------------|--|
| 09:30 – 09:40 | The controversy about Paclitaxel safety – where do we stand? A summary of concerns, available data, and open questions
Andrew Holden |
| 09:40 – 09:45 | FIRST TIME DATA RELEASE: In depth independent safety analysis by Syntactx (CRO) of the Lutonix SFA DCB
Kenneth Ouriel |
| 09:45 – 09:50 | FIRST TIME DATA RELEASE: Paclitaxel exposure and dosage of drug-coated balloons for the treatment of PAD: Exploring mortality rates by regions around the globe
Peter Schneider |
| 09:50 – 09:55 | New long-term information on PTX coated DCB: 5-year results from the AcoArt study
Xin Jia |
| 09:55 – 10:00 | Latest information on long-term efficacy and safety on the Zilver PTX programme
Thomas Zeller |
| 10:00 – 10:05 | Mortality after use of Paclitaxel-based devices in peripheral arteries: A real-world safety analysis
Eva Freisinger |
| 10:05 – 10:12 | The presence and the future of drug-coated devices: What to expect in the next 5 years?
William Gray |
| 10:12 – 10:17 | Panel discussion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Christian Wissgott

Page 2/2

Tuesday, January 28, 2020

FOCUS ON NEW EFFICACY DATA AND NEW APPROACHES

- | | |
|---------------|--|
| 10:17 – 10:22 | FIRST TIME DATA RELEASE: COMPARE-RCT of low dose vs. high dose Paclitaxel coated balloons: 1-year results of the full cohort
Sabine Steiner |
| 10:22 – 10:27 | FIRST TIME DATA RELEASE: 6-month results from Lutonix SFA Japan PMS update
Yoshimitsu Soga |
| 10:27 – 10:32 | FIRST TIME DATA RELEASE: Illumenate 4-year update
Sean Lyden |
| 10:32 – 10:37 | Drug-coated balloon angioplasty of femoropopliteal lesions maintained superiority over standard balloon – 2-year results of the randomized EffPac trial
Dierk Scheinert |
| 10:37 – 10:42 | RANGER II SFA: Randomized trial of RANGER DCB vs. PTA in the SFA
Marianne Brodmann |
| 10:42 – 10:47 | The DCB dose difference: A comparison of drug in tissues of different .018 DCBs
Andrew Holden |
| 10:47 – 10:52 | Post-DCB dissection repair: 12-month results from TOBA III
Christian Wissgott |
| 10:52 – 11:00 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.